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The acyl-chain composition of the major mammalian
phospholipid phosphatidylcholine (PC) is distinct
in various tissues. Although it was classically
suggested that PC diversity is acquired through
acyl-chain remodeling, the mechanisms and bio-
logical relevance of acyl-chain diversity remain
unclear. Here, we show that differences in the sub-
strate selectivity of lysophospholipid acyltrans-
ferases regulate tissue PC acyl-chain composition
through contribution of both the de novo and re-
modeling pathways, depending on the fatty acid spe-
cies. Unexpectedly, while dipalmitoyl-PC (DPPC) is
enriched through the remodeling pathway, several
polyunsaturated PC molecules accumulate during
the de novo pathway. We confirmed this concept
for DPPC in pulmonary surfactant and showed that
the biophysical properties of this lipid are important
to prevent the early onset of acute lung injury. We
propose a model of harmonized processes for phos-
pholipid diversification to satisfy in vivo require-
ments, with an example of its biological relevance.
INTRODUCTION
Phosphatidylcholine (PC) (Figures S1A and S1B) is the major
phospholipid in cellular membranes and pulmonary surfactant
in mammals (van Meer et al., 2008). PC acyl-chain composition
(hereafter referred to as ‘‘PC composition’’) is highly diverse,
especially at the sn-2 position, consisting of fatty acids with var-
iable chain lengths and degrees of unsaturation (Figure S1C)
(MacDonald and Sprecher, 1991; Yamashita et al., 2014). Lipid
diversity is an attractive field of research. Multiple studies have
shown that the acyl-chain composition of phospholipids
(including PC) is affected during various diseases such as cancer
(Morita et al., 2013), nonalcoholic steatohepatitis (Puri et al.,Cel2009), or acute respiratory distress syndrome (Ashton et al.,
1992). In addition, recent studies have shown that the ability of
PC to activate some nuclear receptors depends on its acyl-chain
composition (Chakravarthy et al., 2009; Lee et al., 2011; Liu et al.,
2013). It has been shown that acyl-chain composition affects the
physical properties of PC in vitro (Huang, 2001). Since different
tissues and cell types have distinct PC composition, the physical
properties of their membranes should theoretically be different.
However, the biological relevance of correct composition
together with the physical properties in each tissue of PC re-
mains unclear in vivo. One reason might be that the regulatory
mechanisms explaining the differences in tissue PC composition
are only partially understood.
Acyl chains are incorporated into the sn-2 position of the glyc-
erol backbone of PC by lysophospholipid acyltransferases
(LPLATs) via two distinct pathways: the de novo and remodeling
pathways (Figures 1A and 1B) (MacDonald and Sprecher, 1991;
Shindou and Shimizu, 2009; Yamashita et al., 2014). In the de
novo pathway, the acyl chain from acyl-coenzyme A (acyl-
CoA) is incorporated by lysophosphatidic acid acyltransferases
(LPAATs) into lysophosphatidic acid, generating phosphatidic
acid (PA). PA is then converted to diacylglycerol, which is the
direct precursor of PC. Once synthesized, PC is subjected to
remodeling, in which it loses one acyl chain to generate lyso-
phosphatidylcholine (LPC) and acquires a novel acyl chain
from acyl-CoA (reacylation). This reacylation is catalyzed by
LPC acyltransferases (LPCATs) (Figure 1A). Over the last
decade, four LPCATmolecules (LPCAT1–LPCAT4) with different
acyl-CoA selectivities and tissue distributions were identified by
our group and others (Nakanishi et al., 2006; Chen et al., 2006;
Shindou et al., 2007; Hishikawa et al., 2008; Zhao et al., 2008;
Shimizu, 2009).
It has been suggested that reacylation by LPCATs is critical for
the regulation of PC composition, especially for the accumula-
tion of polyunsaturated fatty acids (PUFAs) at the sn-2 position
(MacDonald and Sprecher, 1991; Rong et al., 2013). However,
no previous study has comprehensively analyzed the acyl-CoA
selectivity of LPCAT activity in various tissues or cells and
compared it to PC composition. Therefore, it was not
clear whether LPCAT acyl-CoA selectivity could explain thel Metabolism 20, 295–305, August 5, 2014 ª2014 Elsevier Inc. 295
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Figure 1. Factors that Might Affect PC
Composition
(A) Factors that might affect the fatty acid pool and/
or PC composition are illustrated. Enzymatic
pathways shown in magenta are those in which a
fatty acid is incorporated at the sn-2 position of a
lysophospholipid.
(B) Schematic illustration of changes in metabo-
lites during the de novo and remodeling pathways.
See also Figure S1 for more detailed information
about lipid structures.
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Diversification Mechanism for Phosphatidylcholinedifferences in PC composition in distinct tissues. We recently
showed that the acyl-CoA selectivity of LPAAT activity might
also affect PC composition, which further complicates the regu-
lation of PC composition (Koeberle et al., 2010). In addition,
differences in tissue acyl-CoA pools caused by variations in fatty
acid synthesis, intake, elongation, desaturation, and activation
might also affect PC composition (Figure 1A) (Guillou et al.,
2010). Therefore, it remains to be understood how the acyl-
CoA selectivity of LPLAT activity (LPAAT and LPCAT activities)
and acyl-CoA pools affect tissue PC composition. Understand-
ing this will enable functional analysis of specific PC species
in vivo by identifying the key enzymes required for their
enrichment.
One important target PC species is dipalmitoyl-PC (DPPC).
DPPC is a disaturated PC species enriched in the lungs as the
major component of pulmonary surfactant (Jobe and Ikegami,
2001; Whitsett et al., 2010). Pulmonary surfactant decreases
the surface tension of the alveoli, and its dysfunction is related
to pulmonary diseases (Jobe and Ikegami, 2001; Whitsett
et al., 2010; Matthay and Zemans, 2011). Therefore, pulmonary
surfactant provides an important model for analyzing the rele-
vance of the physical properties of PC. Although the importance
of high amounts of DPPC in pulmonary surfactant has been
suggested in vitro (Veldhuizen et al., 2000), the mechanism and
biological relevance of such enrichment are incompletely under-
stood in vivo. Previous studies have implicated LPCAT1 in the
synthesis of pulmonary surfactant PC in cell lines and in mice
(Bridges et al., 2010; Butler and Mallampalli, 2010; Zou et al.,
2011). However, since early studies have suggested the involve-
ment of both the de novo and remodeling pathways to the syn-
thesis of surfactant DPPC, with the latter slightly dominant, it is
not known how largely LPCAT1 contributes to the enrichment
of DPPC at the molecular level (Agassandian and Mallampalli,
2013). In addition, methods used in previous studies (radioiso-
tope labeling and thin layer chromatography) only provided
partial information on PC composition, which made it impossible
to determine whether LPCAT1 regulates the composition or the
amount of surfactant PC. Indeed, the function of LPCAT1 in vivo296 Cell Metabolism 20, 295–305, August 5, 2014 ª2014 Elsevier Inc.is controversial, because the neonatal
lethality of Lpcat1 gene-trapped mice
was not recapitulated in Lpcat1 sponta-
neous mutant rd11 mice (Bridges et al.,
2010; Friedman et al., 2010).
In this study, by combining results from
enzymatic assays and PC profiling, we
report that levels of only a subset of PCspecies are explained by the acyl-CoA selectivity of LPCAT
activity. Unexpectedly, the acyl-CoA selectivity of LPAAT activity
contributed to the enrichment of some PUFAs in PC. The acyl-
CoA selectivity of LPCAT activity was important for DPPC
enrichment, confirming the importance of LPCAT1. Using
LPCAT1-deficient mice, we found that the physical properties
of DPPC in pulmonary surfactant prevent the early onset of acute
lung injury. Our study provides a regulatory mechanism for PC
composition and evidence that LPLATs regulate the physical
properties of PC to satisfy in vivo requirements.
RESULTS
The De Novo and Remodeling Pathways Differently
Regulate PC Composition
Based on the possible factors that might regulate PC acyl-chain
composition at the sn-2 position, we analyzed the contribution of
the acyl-CoA selectivity of LPAAT and LPCAT activities (Fig-
ure 1A). We first tested whether transient overexpression of
known LPAATs and LPCATs modulates PC composition in Chi-
nese hamster ovary-K1 (CHO-K1) cells (Figures 2A–2E). Protein
expression in the transfectants was confirmed by western blot-
ting (Figure S2A). To simplify the analyses, the following five
abundant PC species with palmitic acid (16:0; the first and
second numbers indicate the number of carbons and double
bonds, respectively; see Figure S1C) at the sn-1 position were
analyzed: dipalmitoyl (16:0-16:0)-PC (DPPC), palmitoyl-oleoyl
(16:0-18:1)-PC (POPC), palmitoyl-linoleoyl (16:0-18:2)-PC
(PLPC), palmitoyl-arachidonoyl (16:0-20:4)-PC (PAPC), and
palmitoyl-docosahexaenoyl (16:0-22:6)-PC (PDPC) (Figures
S1A–S1D). LPAAT1–LPAAT3 and LPCAT1–LPCAT4 were
transiently overexpressed individually in CHO-K1 cells, three
essential fatty acid (EFA, fatty acids that cannot be synthesized
endogenously) species (linoleic [18:2], arachidonic [20:4], and
docosahexaenoic [22:6] acids) were supplemented, and then
the changes in PC compositions were assessed.
The levels of two PC species, DPPC and POPC, increased
following overexpression of LPCAT1 and LPCAT4, respectively
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Figure 2. Regulation of PC Composition by LPLATs in CHO-K1 Cells
(A–E) Levels of DPPC (A), POPC (B), PLPC (C), PAPC (D), and PDPC (E) were measured in CHO-K1 cells supplemented with the essential fatty acids 18:2, 20:4,
and 22:6 after transient overexpression of the indicated LPLAT (n = 8).
(F) Increases in levels of PC species are compared between transient and stable transfectants.
(G–J) The 18:2-CoA selectivity of LPAAT activity (G), 22:6-CoA selectivity of LPAAT activity (H), 16:0-CoA selectivity of LPCAT activity (I), and 18:1-CoA selectivity
of LPCAT activity (J) in transient transfectants are illustrated (n = 3). Data are derived from Figures S2I and S2K. For (A–E) and (G–J), *p < 0.05 and ***p < 0.001
versus mock transfectants. Statistical values are illustrated only for increases. Error bars are SEM. See also Figure S2.
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Diversification Mechanism for Phosphatidylcholine(Figures 2A, 2B, and 2F). In contrast, overexpression of LPCAT2
and LPCAT3 did not augment the level of a specific PC species.
Although statistical significance was not achieved, overexpres-
sion of LPAAT1 and LPAAT2 tended to elevate PLPC levels
with reproducibility (Figures 2C and 2F). No enzyme upregulated
PAPC levels (Figure 2D). Overexpression of LPAAT3 increased
PDPC levels (Figures 2E and 2F), as we previously described
(Koeberle et al., 2010).
Since the changes induced by transient overexpression were
relatively small, we generated CHO-K1 cells that stably express
the enzymes and investigated the changes in PC composition.
These stably transfected cells expressed the enzymes at varying
levels, but little expression of LPCAT4wasobtained (Figure S2B).
LPCAT4might be an enzyme difficult to express stably, since we
met similar low expression in another cell line, Hepa1-6 (data not
shown). Except for LPCAT4, stable expression of enzymes led to
larger changes in PC composition as compared to those induced
by transient transfection (Figures 2F and S2C–S2G). Although
establishment of a method to express LPCAT4 stably is needed
to show POPC regulation by this enzyme with strong emphasis,Celthe increase in POPC levels by transient expression of LPCAT4
was reproducible in multiple experiments (data not shown). In
the stable transfectants, we also observed changes in PAPC
levels, but enzymes of both the de novo and remodeling path-
ways were involved, suggesting a complex mode of regulation
(Figure S2F).
Next, the acyl-CoA selectivity of LPAAT and LPCAT activities
was measured in transfected CHO-K1 cells to determine
whether differences in substrate selectivity explain the afore-
mentioned changes in PC profiles. Both transient and stable
transfectants were analyzed. After incubation of the membrane
proteins with lysophospholipid and an equimolar mixture of
five acyl-CoAs (1 mM each of 16:0-, 18:1-, 18:2-, 20:4-, and
22:6-CoA), the ratio of enzymatic products was measured by
mass spectrometry to calculate acyl-CoA selectivity (see Fig-
ure S1E for the calculation). Under the condition used, enzymatic
products accumulated linearly for at least 10 min (Figure S2H
and data not shown). Transfection with all LPAATs and LPCATs
affected the acyl-CoA selectivity of LPAAT and LPCAT activities
(Figures S2I–S2L). In LPAAT1- and LPAAT2-transfected cells,l Metabolism 20, 295–305, August 5, 2014 ª2014 Elsevier Inc. 297
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Figure 3. PC Composition and LPLAT Activities in Different Tissues
(A) The proportions of five PC species were measured in membrane fractions from various tissues obtained from C57Bl/6 mice. Error bars are SEM (n = 3).
(B and C) The acyl-CoA selectivity of LPAAT activity (B) and LPCAT activity (C) was measured using these same membrane fractions. The total amounts of
reaction products are provided in Figure S3. Error bars are SEM (n = 3).
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Diversification Mechanism for Phosphatidylcholinethe 18:2-CoA selectivity of LPAAT activity increased, whereas in
LPAAT3-transfected cells, the 22:6-CoA selectivity augmented
compared to that in mock-transfected cells (Figures 2G, 2H,
S2I, S2J, S2M, and S2N). Therefore, these results suggest that
augmented incorporation of 18:2 and 22:6 by LPAAT activity in
the de novo pathway contribute to their enrichment in PC
(through enrichment in its precursor PA). In LPCAT1- and
LPCAT4-transfected cells, the 16:0-CoA and 18:1-CoA selec-
tivity of LPCAT activity increased, respectively (Figures 2I, 2J,
S2K, S2L, S2O, and S2P), suggesting that the levels of 16:0
and 18:1 in PC are regulated by enzymes of the remodeling
pathway. Therefore, acyl-CoA selectivity of enzymes in the de
novo and remodeling pathways has different effects on the PC
profile depending on the fatty acid at the sn-2position (Figure 4F).
Comparison of Tissue PC Composition and LPLAT Acyl-
CoA Selectivity
To determine whether the aforementioned observations can
explain the differences in tissue PC composition, we compared
the PC profiles and acyl-CoA selectivity of LPLAT activities in
various tissues. Analysis of the PC composition in lipids ex-
tracted from the membrane fractions of various tissues revealed
their diversity (Figure 3A). The acyl-CoA selectivity of LPAAT
activity differed among the tested tissues (Figures 3B and
S3A). Except for the brain, LPCAT activity was highly selective
for incorporation of linoleic (18:2) and arachidonic (20:4) acids,
whereas the other acyl-CoA species were minor substrates (Fig-
ures 3C and S3B). To determine whether variability in the acyl-
CoA selectivity of LPLAT activities might explain the different
PC profiles observed, we plotted the acyl-CoA selectivity of
LPAAT or LPCAT activities against the PC profiles determined
above (Figures 4A–4D and S4A–S4J). Calculation of the correla-
tion coefficients showed that the 18:2- and 22:6-CoA selectivity
of LPAAT activity explains the amount of 18:2- and 22:6-contain-
ing PC, respectively, better than the selectivity of LPCAT activity
(Figures 4A, 4B, and 4E). The relatively low correlation coefficient
between 22:6-CoA selectivity of LPAAT and PDPC levels is ex-
plained by the presence of the liver as an outlier, where PDPC
level is increased by the liver-specific phosphatidylethanolamine
methyltransferase (Figures 1A and 4B) (Watkins et al., 2003). The
16:0-CoA and 18:1-CoA selectivity of LPCAT activity explains298 Cell Metabolism 20, 295–305, August 5, 2014 ª2014 Elsevier Incthe amount of 16:0- and 18:1-containing PC, respectively, better
than the selectivity of LPAAT activity (Figures 4C–4E). These ob-
servations are highly consistentwith the results obtained from the
studies in CHO-K1 cells, suggesting that the rate of 18:2 and 22:6
incorporation in the de novo pathway affects their levels in PC
(through their enrichment in its precursor, PA), whereas in the
caseof 16:0 and18:1, the contribution of the remodelingpathway
is higher (Figure 4F). Neither activity alone could explain the pro-
files of 20:4-containing PC, similar to the case of CHO-K1 cells.
LPCAT1 Regulates DPPC Levels In Vivo
The regulatory mechanism proposed above is a useful starting
point for analyzing the relevance of the physical properties of a
specific PC species in vivo, because it explains the target
enzyme to modulate the levels of the lipid of interest. As a proof
of concept, we decided to analyze DPPC function in vivo
because this lipid provides a good model to investigate the
relevance of the physical properties of PC (as is explained in
detail in the Introduction).
Analysis of LPCAT1 protein expression revealed the highest
expression in the lung, followed by the spleen and brain, consis-
tent with the 16:0-CoA selectivity of LPCAT activity in these
tissues (Figures 3C and 5A). We generated LPCAT1-deficient
C57BL/6 mice that lack exon 3, which encodes a region of the
protein containing a histidine residue (His135) critical for LPCAT1
activity (Harayama et al., 2008) (Figures S5A–S5C). LPCAT1 defi-
ciency had a negligible effect on LPAAT activity (Figure 5B). On
the other hand, the 16:0-CoA selectivity of LPCAT activity was
drastically diminished in the lung and spleen of LPCAT1-deficient
mice, reaching a low level similar to the heart (black columns in
Figure 5C). Consistently, LPCAT1-deficient mice had reduced
levels of DPPC in the lung and spleen, while such decrease was
not seen in theheart (Figures 5D–5F). These results areconsistent
with and partially confirm the proposed regulatory mechanism of
PCdiversification (Figure 4F). LPCAT1-deficientmicewere viable
and born consistent with Mendel’s rule (Figure S5D).
A High Level of DPPC Is Required for Full Pulmonary
Surfactant Function
Given the proposed role of LPCAT1 in pulmonary surfactant PC
synthesis, the amount and composition of PC in the pulmonary.
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Figure 4. Relationship between LPLAT
Activity and PC Composition in Different
Tissues
(A–D) The acyl-CoA selectivity of LPLAT activity
was plotted against the amount of the compared
PC species in various tissues. The 18:2-CoA
selectivity of LPAAT (A), 22:6-CoA selectivity of
LPAAT (B), 16:0-CoA selectivity of LPCAT (C), and
18:1-CoA selectivity of LPCAT (D) activities are
compared to PLPC (A), PDPC (B), DPPC (C), and
POPC (D), respectively. The axes are log scale.
Error bars are SEM (n = 3).
(E) Pearson’s correlation coefficients were calcu-
lated from the raw data shown in Figure S4.
(F) We propose a hypothesis explaining the
different contribution of LPAAT and LPCAT acti-
vities to the regulation of PC composition, de-
pending on the sn-2 fatty acid species.
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Diversification Mechanism for Phosphatidylcholinesurfactant of LPCAT1-deficient mice were determined. Bron-
choalveolar lavage (BAL) was performed to analyze pulmonary
surfactant PC and alveolar cell number. The amounts of PC
and cell counts in BAL fluid (BALF) from wild-type (WT) and
LPCAT1-deficient mice were similar (Figures 6A and S6A). In
contrast, the PC composition was drastically different; DPPC
level was nearly one-half of that in WT mice, and other PC spe-
cies were increased (Figure 6B). Additional analyses suggested
that palmitoyl-myristoyl-PC and palmitoyl-palmitoleoyl-PC
levels, both being important components of pulmonary surfac-
tant (Postle et al., 2006), are also decreased in LPCAT1-deficient
mice (Figure S6B). Since secretory phospholipase activity was
almost undetectable in BALF, the changes in PC composition
are not explained by its degradation in LPCAT1-deficient mice
(Figure S6C). This observation is consistent with the normal
surfactant PC amount. Bridges et al. previously showed that
the surface tension-lowering ability of pulmonary surfactant
from LPCAT1-deficient mice is lower than that of surfactant
from WT mice (Bridges et al., 2010). To determine whether a
change in PC composition can indeed affect the properties of
pulmonary surfactant, we measured the surface tension-
lowering abilities of various mixtures that mimic pulmonary sur-
factant using a Langmuir-Wilhelmy balance. Based on previous
studies, we included phosphatidylglycerol (PG), 16:0, and sur-
factant protein (SP)-C in the mixtures for full activity (Figure 6C)Cell Metabolism 20, 295–3(Otsubo and Takei, 2002). The addition
of DPPC to this mixture drastically
reduced the minimal surface tension to
near zero (Figure 6C). To examine the ef-
fect of PC composition, 25%, 50%, or
75% DPPC was replaced by equimolar
POPC. Increasing POPC levels reduced
surfactant function (Figure 6C). Therefore,
PC composition is very important for
maintaining normal pulmonary surfactant
activity.
The surface tension-lowering ability of
surfactant decreases the static elastance
(a parameter reflecting lung stiffness) of
the lungs, which is also affected by theelastic properties of this tissue (Suki and Bates, 2011). When
we analyzed the pressure-volume (P-V) relationships, the calcu-
lated static elastance tended to be lower in LPCAT1-deficient
mice than in WT mice (Figures 6D and 6E). To discriminate the
effects of tissue elasticity and surface tension on static ela-
stance, we also analyzed the P-V relationships after removing
the pulmonary surfactant and reinflating the lungs with air (Fig-
ure 6D). After the procedure, elastance increased due to the
increased surface tension caused by pulmonary surfactant loss
(Figure 6E) (Suki and Bates, 2011). Thus, the difference in static
elastance reflects the surface tension-lowering ability of the
removed pulmonary surfactant (which we will call the ‘‘ela-
stance-lowering property’’). As expected, the elastance-
lowering property of surfactant from LPCAT1-deficient mice
was lower than that of surfactant from WT mice (Figure 6F).
This shows that, consistent with the in vitro data (Figure 6C),
LPCAT1-deficient mice have lower pulmonary surfactant
function in situ. This also suggests that measurement of static
elastance before and after BAL allows for easy estimation of
the pulmonary surfactant function in a single mouse. Airway
resistance was similar between WT and LPCAT1-deficient
mice (Figure S6D).
Our data show that LPCAT1 affects PC composition and the
surface tension-lowering ability of pulmonary surfactant. These
changes seemed not to be due to reductions in surfactant05, August 5, 2014 ª2014 Elsevier Inc. 299
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Figure 5. LPCAT1 Regulates DPPC Levels In Vivo
(A) The distribution of LPCAT1 in tissues from C57Bl/6 mice was analyzed by western blotting.
(B–F) Differences in acyl-CoA selectivity of LPAAT (B) and LPCAT (C) activities and in PC composition (D–F) weremeasured inmembrane fractions of tissues from
mice of the indicated genotypes. *p < 0.05; **p < 0.01; and #, p < 0.0001 versus WT mice. Error bars are SEM (n = 3). See also Figure S5.
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Diversification Mechanism for Phosphatidylcholineproteins, since the mRNA levels of SP-A, SP-B, SP-C, and SP-D
and protein levels of SP-B and SP-C were not decreased in
LPCAT1-deficient mice (Figures S6E–S6H). Therefore, our re-
sults provide an example of how the physical properties of PC
are regulated by an LPLAT.
High Levels of DPPC in Surfactant Are Required to
Prevent an EarlyOnset of Ventilator-Induced Lung Injury
Since LPCAT1-deficient mice were viable and did not show any
apparent abnormality, we speculated that this enzyme might be
relevant under pathological conditions.We analyzed the suscep-
tibility of these mice to ventilator-induced lung injury (VILI)
caused by mechanical damage during high tidal volume (HVt)
ventilation (Dreyfuss and Saumon, 1998). Since pulmonary sur-
factant inactivation occurs in the early phases of VILI (Dreyfuss
and Saumon, 1998), we measured surfactant functions (similarly
to Figures 6D–6F) in mice that were nonventilated, low tidal vol-
ume (LVt) ventilated, or HVt ventilated for 30 min. Surfactant
inactivation indeed occurred after as little as 30 min of HVt venti-
lation in both WT and LPCAT1-deficient mice (Figure 7A).
Although the surfactant function decreases observed in HVt-
ventilated WT and LPCAT1-deficient mice were similar, it was
almost completely abolished in LPCAT1-deficient mice due to
the low baseline function (Figure 7A). Consistently, HVt-venti-
lated LPCAT1-deficient mice displayed rapid increases in dy-
namic elastance (E, this parameter was selected because it
takes less time to measure than static elastance), as well as
airway resistance, which were apparent in the first 30 min (Fig-
ures 7B and S7A). Blood oxygenation dropped and was followed
by death in LPCAT1-deficient mice, which occurred earlier than
in WTmice (Figures 7C and S7B). When mice received LVt venti-
lation, both WT and LPCAT1-deficient mice survived 6 hr of
ventilation without any change in E (data not shown).
To determine if low DPPC levels in pulmonary surfactant
contribute to the early increases in E of LPCAT1-deficient mice300 Cell Metabolism 20, 295–305, August 5, 2014 ª2014 Elsevier Incduring HVt ventilation, we intratracheally administered DPPC
or POPC and monitored changes in E (note that the ventilation
protocol was modified as described in the Experimental Proce-
dures). A mixture of PG, 16:0, and SP-C was used as the vehicle
(Otsubo and Takei, 2002). Baseline E values tended to be lower
in DPPC-treated mice than in vehicle- or POPC-treated mice
(Figure 7D). After 30 min of HVt ventilation, E increased in
vehicle- and POPC-treated mice, whereas almost no change
was seen in DPPC-treated mice (Figure 7D). Consequently, E
values became lower in DPPC-treated mice than in other mice
(Figure 7D). Therefore, a normal proportion of DPPC is protective
against early increases in E.
At later stages (after 60–90 min of ventilation), pulmonary
edema occurred, and alveolar wall thickening and deformation
were observed histologically (Figures S7C and S7D). These
histological changes were not seen in LVt-ventilated mice or in
80% (4/5) of the HVt-ventilated WT mice (Figure S7D). At these
time points, the mRNA levels of various cytokines, chemokines,
and stress markers were measured by semiquantitative PCR.
The mRNA levels of inflammatory cytokines/chemokines such
as interleukin-6 (IL-6), IL-1b, tumor necrosis factor-a (TNF-a),
chemokine (C-X-C) ligand 1 (CXCL1), and CXCL2 were higher
in HVt-ventilated mice than in LVt-ventilated mice, and these
changes were even higher in LPCAT1-deficient mice than in
WT mice (Figure S7E).
We next determined if the early loss of surfactant function
in LPCAT1-deficient mice leads to inflammatory mediator pro-
duction. Due to the early time course of the disease, we focused
on danger molecules and lipid mediators, which are produced
without gene transcription (Shimizu, 2009; Tolle and Standiford,
2013). Among the three danger molecules tested (high mobility
group box 1 [HMGB1], S100 calcium binding protein A8/9, and
heat shock protein 70), we only detected HMGB1 in BALF. While
total BALF protein was similar between groups, HMGB1 levels
were higher in HVt-ventilated mice than in LVt-ventilated mice.
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Figure 6. LPCAT1 Regulates Pulmonary Sur-
factant Composition and Function
(A and B) PC amount is unchanged (A, n = 17), but
PC composition is altered (B, n = 6) in BALF from
LPCAT1-deficient mice.
(C) A high percentage of DPPC is required to ach-
ieve effective surface tension-lowering ability by
pulmonary surfactant mimetics (n = 3). ***p < 0.001
versus samples containing 100% DPPC.
(D–F) The pressure-volume relationship (D) inmouse
lungs was measured before and after pulmonary
surfactant removal to calculate static elastance (E)
and surfactant function (F) (n = 14). *p < 0.05 and
****p < 0.0001 versus WT mice. (A–E) Error bars are
SEM. See also Figure S6.
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Diversification Mechanism for Phosphatidylcholine(Figures S7F and S7G). However, HMGB1 levels in HVt-venti-
lated WT mice and LPCAT1-deficient mice were similar (Fig-
ure S7G). We measured the lipid mediator profiles in lungs
from nonventilated, LVt-ventilated, and HVt-ventilated (30 min)
mice using a targeted lipidomics approach (Kita et al., 2005).
Among the various lipidmediators measured, the levels of leuko-
triene D4 (LTD4) and platelet-activating factor (PAF) were
increased in HVt-ventilated LPCAT1-deficient but not in HVt-
ventilated WT mice (Figure 7E and Table S1). In addition, the
levels of these two mediators were lower in LPCAT1-deficient
mice that received intratracheal DPPC (plus the vehicle
mentioned above) than in mice that received vehicle alone (Table
S2). To confirm the contribution of lipid mediators in the patho-
genesis of LPCAT1-deficient mice, we administered an inhibitor
of leukotriene biosynthesis (MK 886), or an antagonist of PAF
receptor (ABT 491), or other inhibitors before 60min of HVt venti-
lation, and measured the changes in E and edema. Among the
inhibitors tested, only MK 886 tended to effectively change
both E and edema (Figures S7H and S7I). We increased the
number of mice administered MK 886 and found that this com-
pound inhibited the increase in E and edema formation in HVt-
ventilated LPCAT1-deficient mice (Figures 7F, 7G, and S7J).
MK 886 was effective in suppressing the changes in E at late
time points (30–60 min) (Figures 7F and 7G). Importantly, MK
886 did not inhibit the early increases in E seen in LPCAT1-defi-
cient mice during the first 30 min of HVt ventilation (Figures 7F
and 7G). Since administration of DPPC, but notMK886, inhibited
the early increases in E, we concluded that such changes were
caused by early loss of surfactant function in LPCAT1-deficient
mice, while the later changes were caused by the inflammatory
responses that occurred in these mice. Therefore, the physical
properties of DPPC are required to maintain high basal surfac-
tant activity, preventing the early onset of VILI.
DISCUSSION
Revising the Regulatory Mechanisms of Tissue PC
Composition
It has been thought that PC acyl-chain diversification and PUFA
accumulation occur during the remodeling pathway (MacDonald
and Sprecher, 1991; Rong et al., 2013). We re-examined thisCelhypothesis by comparing the acyl-CoA selectivity of LPLAT
activity and PC composition in cells and tissues from the whole
body. Our results show that, in contrast to the traditional hypoth-
esis, the acyl-CoA selectivity of not only LPCAT activity but also
LPAAT activity has a substantial impact on PC composition, and
that the latter contributes to the enrichment of PUFAs such as
18:2 and 22:6.We need to emphasize that we previously showed
that knockdown of the 18:2- and 20:4-CoA selective LPCAT,
LPCAT3, decreased the levels of 18:2 and 20:4 in PC (Hishikawa
et al., 2008). Therefore, it is clear that acyl-chain remodeling of
PC is extensive and that this remodeling is important for the
maintenance of baseline amounts of 18:2 and 20:4. However, if
the enzyme is present in sufficient amounts (as it should be in
normal animals), other factors have greater contribution to the
amounts of 18:2 and 20:4 in PC than LPCATs and thus provide
a better explanation for the differences in PC observed in various
tissues. Such factors for the enrichment of 20:4 into PC have to
be established, but differences in 20:4-CoA levels between tis-
sues, as well as a complex regulation by both LPAATs and
LPCATs, might exist. Our proposal is summarized in Figure 4F
and provides a revised concept of how PC composition is regu-
lated in different tissues and cells. The revised model proposes
that in the PC diversification process, LPAAT activity, LPCAT
activity, and the acyl-CoA pool act in a harmonized manner
and that the relative contribution of each factor differs depending
on the fatty acid species. This model explains well why an
enzyme of the remodeling pathway, LPCAT1, is required for
the accumulation of the disaturated DPPC.
Possible Underlying Mechanisms Explaining the
Different Contributions of LPLATs
Since 16:0 and 18:1 are both NEFAs and 18:2 and 22:6 are EFAs
(Le et al., 2009), our results raise the possibility that the contribu-
tions of LPAATs and LPCATs differ depending on whether the
fatty acid can be synthesized in the cell or not. It is possible
that such differences affect the amount and/or stability of sub-
strate supply or the compartments of cells where acyl-CoAs
and phospholipids are synthesized. However, precise analyses
need to be performed to obtain a complete understanding.
It is intriguing that, although extensive remodeling occurs after
de novo synthesis, the acyl-CoA selectivity of LPCAT activityl Metabolism 20, 295–305, August 5, 2014 ª2014 Elsevier Inc. 301
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Figure 7. A High Level of DPPC Prevents Early Surfactant Dysfunction and VILI Onset
(A) Pulmonary surfactant functions were measured in mice ventilated for 30 min (n = 6). *p < 0.05 and **p < 0.01 versus LVt-ventilated mice of the same genotype.
(B and C) Mice were subjected to HVt ventilation, and then changes in dynamic elastance (B) and survival (C) were analyzed. **p < 0.01 and ****p < 0.0001.
(D) Vehicle (saline with phosphatidylglycerol, 16:0, and SP-C) or vehicle plus the indicated PC specieswas administered intratracheally to LPCAT1-deficientmice.
Dynamic elastance was measured before and after 30 min of HVt ventilation (n = 4).
(E) Levels of LTD4 were measured in the lungs of mice ventilated for 30 min (n = 5).
(F and G) Mice were administered vehicle (Ve) or MK 886 (MK) intravenously, received HVt ventilation, and dynamic elastance was monitored (n = 3–8). (G) The
increases in dynamic elastance during the first 30 min (0–30 min) and the following 30min (30–60 min) are illustrated separately. **p < 0.01. For (A), (B), and (D–G),
error bars are SEM. See also Figure S7 and Tables S1 and S2.
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Diversification Mechanism for Phosphatidylcholinehas a small effect on the amount of PUFAs in PC. This observation
suggests that in a tissue where a PUFA species is preferentially
introduced at the sn-2 position of LPC, the PUFA-PC that has
been produced is preferentially degraded, probably into LPC.
This hypothesis might be in accordance with the recent proposal
of Yamashita et al., suggesting the important role for the reverse
reaction of LPCATs in the production of LPC (Yamashita et al.,
2014). If thisLPCproductionpathway isdominant to thatmediated
by phospholipases, increased LPCAT activity alsomeans that the
produced pool of PUFA-containing PC is preferentially recon-
verted to LPC. To test this hypothesis, the major LPC-producing
enzymes involved in the remodelingpathwayneed tobe identified.
The fact that the correlation coefficients in Figure 3 are not
complete shows that additional factors affect PC composition.
These factors include differences in acyl-CoA pools, the rate
and selectivity of de novo PC supply, the selectivity and velocity
of PC degradation, the transport and compartmentalization of
PC, and the extent of polar head exchange. The correlation
coefficients provided in this study (Figures 4A–4E and S4A–
S4J) show the magnitude of the contribution of LPAAT or LPCAT
activities to the amount of a specific PC species, relative to these
other factors.
Analysis of In Vivo Functions of Lung DPPC Using
LPCAT1-Deficient Mice
Based on the proposed model of PC diversification, we could
analyze a specific PC molecule in vivo by depleting the appro-
priate target enzyme. We chose pulmonary surfactant DPPC
as the primary target since it is easier to analyze a secreted lipid
and because it provides a goodmodel for studying the relevance302 Cell Metabolism 20, 295–305, August 5, 2014 ª2014 Elsevier Incof the physical properties of PC. Although it has been long recog-
nized that DPPC is the major component of pulmonary surfac-
tant, the biological relevance of this enrichment in vivo was not
fully understood (Jobe and Ikegami, 2001). Investigation of
LPCAT1-deficient mice enabled the analysis of DPPC function
in vivo, since only PC composition and not amount was changed
in pulmonary surfactant of these mice.
Our results show that LPCAT1 is important for preventing the
early onset of VILI during HVt ventilation. The intratracheal
administration experiments (Figure 7D) strongly suggest that
DPPC enrichment is critical for maintaining high pulmonary
surfactant activity over the threshold for VILI onset. Therefore,
one major explanation for the phenotypes seen in LPCAT1-
deficient mice is that their surfactant activity is near the threshold
under which VILI occurs. Although LTD4 has been implicated in
the worsening of LPCAT1-deficient mice and is consistent with
previous studies of 5-lipoxygenase-deficient mice (Caironi
et al., 2005), it is clear that lipid mediators act in a concerted
manner. We cannot rule out the contribution of other factors
such as prostaglandins or other leukotrienes, thus drugs other
than MK 886 might also be effective depending on dosages or
administration routes. Our interpretation is that DPPC insuffi-
ciency led to a fatal lipid mediator imbalance, as a consequence
of decreased surfactant functions.
Bridges et al. showed that LPCAT1 gene-trapped mice have
partial neonatal lethality due to a respiratory distress, unlike in
our mice (Bridges et al., 2010). Analyzing the commonalities
between different reports should provide critical insights into
LPCAT1 function in the lung. Differences in the genetic
backgrounds might explain the discrepancies in the neonatal.
Cell Metabolism
Diversification Mechanism for Phosphatidylcholinebreathing of the various LPCAT1-deficient mouse models. It is
reasonable to think that there is a minimal value of surfactant
activity required for the first breaths after birth. This threshold
might differ by genetic backgrounds, due to differences in gesta-
tion periods, lung morphologies, or other factors. Therefore,
although the outcomes differ, these LPCAT1-deficient mice
share a common phenotype: surfactant activity levels near the
thresholds of respiratory dysfunctions. This shows that the phys-
ical properties of DPPC are important to maintain high surfactant
activity to prevent respiratory failure.
Conclusions, Biological Relevance, and Future
Perspectives
In this study, we found how the differences in tissue PC com-
position are generated and provide a revised view of the contri-
bution of different LPLAT enzymes during the PC diversification.
In addition, our study is one of the first reports to show that
LPLAT activity regulates the physical properties of phospho-
lipids in vivo, in a biologically relevant manner.
Driven by the recent advances in the field of lipidomics, there is
accumulating evidence that many changes in lipid composition
occur in various diseases (Ashton et al., 1992; Puri et al., 2009;
Wenk, 2010; Morita et al., 2013). Membrane phospholipids serve
as precursors for multiple lipid mediators, and thus abnormal
composition can lead to aberrant lipid mediator production (Shi-
mizu, 2009). Our results raise the possibility that LPAATs affect
the levels of 18:2- and 22:6-derived lipid mediators, such as
hydroxyoctadecadienoic acid species and D-series resolvins
(Obinata et al., 2005; Buckley et al., 2014). Also, the changes in
phospholipid composition affect membrane biophysical proper-
ties and might lead to abnormal functions of membrane proteins
(Fu et al., 2011; Rong et al., 2013). Therefore, our model on PC
diversification will enable the analyses of the underlying mecha-
nisms of such changes andwill help the correct understanding of
related diseases.
EXPERIMENTAL PROCEDURES
Animal Studies
Studies using mice were approved and performed in accordance with the
guidelines of the animal experimentation committee of the University of Tokyo.
Detection of Proteins
Western blot analysis was performed to detect FLAG-tagged LPLATs, endo-
genous LPCAT1, and SP-B. SP-C was detected by liquid chromatography-
tandem mass spectrometry (LC-MS/MS). See Supplemental Experimental
Procedures for a complete description of the methods.
Analysis of PC in Lipid Extracts or Enzymatic Products
CHO-K1 cells were transfected by lipofection or nucleofection and eventually
selected byG418 resistance. Lipids were extracted bymethanol or themethod
of Bligh and Dyer and analyzed by LC-MS/MS or colorimetric assays. See
Supplemental Experimental Procedures for a complete description of the
methods.
Enzymatic Assays
Membrane fractions were prepared by sonication of cells or homogenization of
tissues, followed by centrifugation. LPLAT activity was measured by incu-
bating membrane fractions with substrates at 37C for 10 min. The reaction
mixtures contained 25 mM of deuterium-labeled LPA or LPC and 1 mM each
of 16:0-, 18:1-, 18:2-, 20:4-, and 22:6-CoA. Products were quantified by LC-CelMS/MS. See Supplemental Experimental Procedures for a complete descrip-
tion of the methods.
Generation of LPCAT1-Deficient Mice
Embryonic stem cells fromC57BL/6mice were electroporated with a targeting
vector to obtain a recombinant clone with Lpcat1 exon 3 flanked by loxP sites.
Mice were generated from this clone, and exon 3 was removed by mating with
mice expressing Cre recombinase. See Supplemental Experimental Proce-
dures for a complete description of the methods.
Surface Tension Measurements
Surface tension was measured using a custom-made Langmuir-Wilhelmy
balance. A small volume of surfactant mixture was dropped on the liquid
surface, and surface tension was continuously measured during surface
area cycling, from the force applied to a platinum plate. See Supplemental
Experimental Procedures for a complete description of the methods.
BAL and P-V Analysis
Mice were euthanized by administration of an overdose of pentobarbital
sodium, followed by exsanguination via the abdominal vessels. BAL was
performed by five lavages with 0.8–1 ml of saline through an endotracheal
cannula. P-V analyses were performed before and after lavage, by connecting
the cannula to a ventilator. Quasi-static elastance was calculated from the
slope of the P-V curve. See Supplemental Experimental Procedures for a com-
plete description of the methods.
Quantitative PCR
Total RNA from the mouse lungs was obtained using the RNeasy Mini Kit
(QIAGEN) and reverse transcribed using random primers and SuperScript III
(Invitrogen). Quantitative PCR was performed using the LightCycler (Roche).
The primers used are listed in the Supplemental Information.
Mouse Ventilation
Anesthetized mice were intubated with a 19G cannula and attached to a venti-
lator. ForHVt ventilation, the tidal volumewasset to40ml/kg (except for the intra-
tracheal administration studies) without application of positive end-expiration
pressure (PEEP). When intratracheal administration was performed prior to HVt
ventilation, susceptibility toVILI increased, leading tovery earlydeath. Therefore,
for these experiments, the tidal volume for HVt ventilation was changed to
30 ml/kg. For LVt ventilation, the tidal volume was 10 ml/kg, and PEEP was set
to 3 cmH2O. Dynamic elastance and airway resistance were measured every
30 min using a built-in protocol (‘‘Snapshot’’ protocol). Oxygen saturation was
measured using a pulse oximeter. After the endpoint, the lungs were harvested
for edema determination, RNA extraction, or lipid mediator measurements. In
other cases, the lungswerefixedwith formalin for histological analyses.SeeSup-
plemental Experimental Procedures for a complete description of the methods.
Measurement of sPLA2 Activity, SP-C, Danger Molecules, and Lipid
Mediators
Secretory PLA2 activity was measured using the sPLA2 assay kit (Cayman).
SP-C was measured by LC-MS/MS. Danger molecules were measured by
ELISA. Lipid mediators were purified by solid phase extraction and measured
by LC-MS/MS. See Supplemental Experimental Procedures for a complete
description of the methods.
Statistical Analyses
For comparisons of two groups, unpaired t tests orMann-WhitneyU tests were
used, depending on the distribution of the values. For multiple comparisons,
one-way ANOVA or two-way ANOVA were performed, followed by Dunnett’s
multiple comparison tests or Bonferroni’s multiple comparison tests, depend-
ing on the combinations of comparisons. All analyses were performed using
Prism software (GraphPad).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2014.05.019.l Metabolism 20, 295–305, August 5, 2014 ª2014 Elsevier Inc. 303
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